Long-term effects of early adolescent methamphetamine exposure on depression-like behavior and the hypothalamic vasopressin system in mice

Developmental Neuroscience

Volumn 36, Issue 2, 2014, Pages 108-118

  Joca, Lauren ^a   Zuloaga, Damian G ^b   Raber, Jacob ^b,c   Siegel, Jessica A ^a  

^a UNIVERSITY OF THE SOUTH   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Adolescence; Depression; Methamphetamine; Mice; Vasopressin

Indexed keywords

METHAMPHETAMINE; SODIUM CHLORIDE; VASOPRESSIN; ARGIPRESSIN; VASOPRESSIN DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DRUG EXPOSURE; FEMALE; FORCED SWIM TEST; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LONG TERM EXPOSURE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ADOLESCENT; ADULT; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NERVE CELL; ANIMAL; C57BL MOUSE; COGNITION; DRUG EFFECTS; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; METABOLISM; NEWBORN; PATHOPHYSIOLOGY; SEXUAL DEVELOPMENT; TIME;

ANIMALS; ANIMALS, NEWBORN; ARGININE VASOPRESSIN; BEHAVIOR, ANIMAL; COGNITION; DEPRESSION; FEMALE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; METHAMPHETAMINE; MICE, INBRED C57BL; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; PITUITARY-ADRENAL SYSTEM; SEX CHARACTERISTICS; TIME; VASOPRESSINS;

EID: 84903584823     PISSN: 03785866     EISSN: 14219859     Source Type: Journal    
DOI: 10.1159/000360001     Document Type: Article

References (51)

1. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, Sedler MJ, Gatley SJ, Hitzemann R, Ding YS, Logan J, Wong C, Miller EN: Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001; 158: 377-382. (Pubitemid 32205193)
2. Li SX, Yan SY, Bao YP, Lian Z, Qu Z, Wu YP, Liu ZM: Depression and alterations in hypothalamic-pituitary-adrenal and hypothalamic-pituitary-thyroid axis function in male abstinent methamphetamine abusers. Hum Psychopharmacol 2013; 28: 477-483.
3. Nakama H, Chang L, Cloak C, Jiang C, Alicata D, Haning W: Association between psychiatric symptoms and craving in methamphetamine users. Am J Addict 2008; 17: 441-446.
4. Doremus-Fitzwater TL, Varlinskaya EI, Spear LP: Motivational systems in adolescence: possible implications for age differences in substance abuse and other risk-taking behaviors. Brain Cogn 2010; 72: 114-123.
5. Spear LP, Varlinskaya EI: Sensitivity to ethanol and other hedonic stimuli in an animal model of adolescence: implications for prevention science? Dev Psychobiol 2010; 52: 236-243.
6. Rawson R, Gonzales R, McCann M, Ling W: Use of methamphetamine by young people: is there reason for concern? Addiction 2007; 102: 1021-1022. (Pubitemid 46918684)
7. Spear LP: The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev 2000; 24: 417-463.
8. King G, Alicata D, Cloak C, Chang L: Psychiatric symptoms and HPA axis function in adolescent methamphetamine users. J Neuroimmune Pharmacol 2010; 5: 582-591.
9. King G, Alicata D, Cloak C, Chang L: Neuropsychological deficits in adolescent methamphetamine abusers. Psychopharmacology (Berl) 2010; 212: 243-249.
10. Rawson RA, Gonzales R, Obert JL, McCann MJ, Brethen P: Methamphetamine use among treatment-seeking adolescents in Southern California: participant characteristics and treatment response. J Subst Abuse Treat 2005; 29: 67-74. (Pubitemid 41749336)
11. Anker JJ, Baron TR, Zlebnik NE, Carroll ME: Escalation of methamphetamine self-administration in adolescent and adult rats. Drug Alcohol Depend 2012; 124: 149-153.
12. Zakharova E, Leoni G, Kichko I, Izenwasser S: Differential effects of methamphetamine and cocaine on conditioned place preference and locomotor activity in adult and adolescent male rats. Behav Brain Res 2009; 198: 45-50.
13. North A, Swant J, Salvatore MF, Gamble-George J, Prins P, Butler B, Mittal MK, Heltsley R, Clark JT, Khoshbouei H: Chronic methamphetamine exposure produces a delayed, long-lasting memory deficit. Synapse 2013; 67: 245-257.
14. Vorhees CV, Reed TM, Morford LL, Fukumura M, Wood SL, Brown CA, Skelton MR, McCrea AE, Rock SL, Williams MT: Periadolescent rats (P41-50) exhibit increased susceptibility to D-methamphetamine-induced long-term spatial and sequential learning deficits compared to juvenile (P21-30 or P31-40) or adult rats (P51-60). Neurotoxicol Teratol 2005; 27: 117-134. (Pubitemid 40170412)
15. Zombeck JA, Lewicki AD, Patel K, Gupta T, Rhodes JS: Patterns of neural activity associated with differential acute locomotor stimulation to cocaine and methamphetamine in adolescent versus adult male C57BL/6J mice. Neuroscience 2010; 165: 1087-1099.
16. Kokoshka JM, Fleckenstein AE, Wilkins DG, Hanson GR: Age-dependent differential responses of monoaminergic systems to high doses of methamphetamine. J Neurochem 2000; 75: 2095-2102.
17. Williams MT, Inman-Wood SL, Morford LL, McCrea AE, Ruttle AM, Moran MS, Rock SL, Vorhees CV: Preweaning treatment with methamphetamine induces increases in both corticosterone and ACTH in rats. Neurotoxicol Teratol 2000; 22: 751-759.
18. Grace CE, Schaefer TL, Herring NR, Graham DL, Skelton MR, Gudelsky GA, Williams MT, Vorhees CV: Effect of a neurotoxic dose regimen of (+)-methamphetamine on behavior, plasma corticosterone, and brain monoamines in adult C57BL/6 mice. Neurotoxicol Teratol 2010; 32: 346-355.
19. Aisa B, Tordera R, Lasheras B, Del Rio J, Ramirez MJ: Cognitive impairment associated to HPA axis hyperactivity after maternal separation in rats. Psychoneuroendocrinology 2007; 32: 256-266. (Pubitemid 46400278)
20. Piwowarska J, Chimiak A, Matsumoto H, Dziklinska A, Radziwon-Zaleska M, Szelenberger W, Pachecka J: Serum cortisol concentration in patients with major depression after treatment with fluoxetine. Psychiatry Res 2012; 198: 407-411.
21. Lok A, Mocking RJ, Ruhe HG, Visser I, Koeter MW, Assies J, Bockting CL, Olff M, Schene AH: Longitudinal hypothalamic-pituitary-adrenal axis trait and state effects in recurrent depression. Psychoneuroendocrinology 2012; 37: 892-902.
22. Acevedo SF, Pfankuch T, van Meer P, Raber J: Role of histamine in short-and long-term effects of methamphetamine on the developing mouse brain. J Neurochem 2008; 107: 976-986.
23. Grace CE, Schaefer TL, Herring NR, Skelton MR, McCrea AE, Vorhees CV, Williams MT: (+)-Methamphetamine increases corticosterone in plasma and BDNF in brain more than forced swim or isolation in neonatal rats. Synapse 2008; 62: 110-121.
24. Schaefer TL, Skelton MR, Herring NR, Gudelsky GA, Vorhees CV, Williams MT: Short-and long-term effects of (+)-methamphetamine and (+/-)-3,4- methylenedioxymethamphetamine on monoamine and corticosterone levels in the neonatal rat following multiple days of treatment. J Neurochem 2008; 104: 1674-1685. (Pubitemid 351316773)
25. Williams MT, Blankenmeyer TL, Schaefer TL, Brown CA, Gudelsky GA, Vorhees CV: Long-term effects of neonatal methamphetamine exposure in rats on spatial learning in the Barnes maze and on cliff avoidance, corticosterone release, and neurotoxicity in adulthood. Brain Res Dev Brain Res 2003; 147: 163-175. (Pubitemid 38114706)
26. Desbonnet L, Garrett L, Daly E, McDermott KW, Dinan TG: Sexually dimorphic effects of maternal separation stress on corticotrophinreleasing factor and vasopressin systems in the adult rat brain. Int J Dev Neurosci 2008; 26: 259-268.
27. Zuloaga DG, Siegel JA, Acevedo SF, Agam M, Raber J: Developmental methamphetamine exposure results in short-and long-term alterations in hypothalamic-pituitary-adrenalaxis-associated proteins. Dev Neurosci 2013; 35: 338-346.
28. Herman JP, Cullinan WE: Neurocircuitry of stress: central control of the hypothalamo-pituitary-adrenocortical axis. Trends Neurosci 1997; 20: 78-84. (Pubitemid 27050702)
29. Acevedo SF, de Esch IJ, Raber J: Sex-and histamine-dependent long-term cognitive effects of methamphetamine exposure. Neuropsychopharmacology 2007; 32: 665-672.
30. Siegel JA, Craytor MJ, Raber J: Long-term effects of methamphetamine exposure on cognitive function and muscarinic acetylcholine receptor levels in mice. Behav Pharmacol 2010; 21: 602-614.
31. Siegel JA, Park BS, Raber J: Long-term effects of neonatal methamphetamine exposure on cognitive function in adolescent mice. Behav Brain Res 2011; 219: 159-164.
32. Vorhees CV, Inman-Wood SL, Morford LL, Broening HW, Fukumura M, Moran MS: Adult learning deficits after neonatal exposure to D-methamphetamine: selective effects on spatial navigation and memory. J Neurosci 2000; 20: 4732-4739. (Pubitemid 30396638)
33. Vorhees CV, Skelton MR, Williams MT: Agedependent effects of neonatal methamphetamine exposure on spatial learning. Behav Pharmacol 2007; 18: 549-562. (Pubitemid 47356381)
34. Williams MT, Morford LL, Wood SL, Wallace TL, Fukumura M, Broening HW, Vorhees CV: Developmental D-methamphetamine treatment selectively induces spatial navigation impairments in reference memory in the Morris water maze while sparing working memory. Synapse 2003; 48: 138-148. (Pubitemid 36444339)
35. Slamberova R, Mikulecka A, Pometlova M, Schutova B, Hruba L, Deykun K: The effect of methamphetamine on social interaction of adult male rats. Behav Brain Res 2010; 214: 423-427.
36. Good RL, Radcliffe RA: Methamphetamineinduced locomotor changes are dependent on age, dose and genotype. Pharmacol Biochem Behav 2011; 98: 101-111.
37. Good RL, Liang LP, Patel M, Radcliffe RA: Mouse strain-and age-dependent effects of binge methamphetamine on dopaminergic signaling. Neurotoxicology 2011; 32: 751-759.
38. Clement Y, Calatayud F, Belzung C: Genetic basis of anxiety-like behaviour: a critical review. Brain Res Bull 2002; 57: 57-71. (Pubitemid 34097771)
39. File SE, Seth P: A review of 25 years of the social interaction test. Eur J Pharmacol 2003; 463: 35-53. (Pubitemid 36205071)
40. Matsuo N, Takao K, Nakanishi K, Yamasaki N, Tanda K, Miyakawa T: Behavioral profiles of three C57BL/6 substrains. Front Behav Neurosci 2010; 4: 29.
41. Franklin K, Paxinos G: The Mouse Brain in Stereotaxic Coordinates. San Diego, Academic Press, 1997.
42. Cruickshank CC, Dyer KR: A review of the clinical pharmacology of methamphetamine. Addiction 2009; 104: 1085-1099.
43. Dunlop BW, Nemeroff CB: The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007; 64: 327-337. (Pubitemid 46376789)
44. Owens MJ, Nemeroff CB: Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 1994; 40: 288-295. (Pubitemid 24072594)
45. Volz TJ, Farnsworth SJ, Rowley SD, Hanson GR, Fleckenstein AE: Age-dependent differences in dopamine transporter and vesicular monoamine transporter-2 function and their implications for methamphetamine neurotoxicity. Synapse 2009; 63: 147-151.
46. Siegel JA, Park BS, Raber J: Methamphetamine exposure during brain development alters the brain acetylcholine system in adolescent mice. J Neurochem 2011; 119: 89-99.
47. Zuloaga DG, Johnson LA, Agam M, Raber J: Sex differences in activation of the hypothalamic-pituitary-adrenal axis by methamphetamine. J Neurochem 2014, Epub ahead of print.
48. Rood BD, Stott RT, You S, Smith CJ, Woodbury ME, De Vries GJ: Site of origin of and sex differences in the vasopressin innervation of the mouse (Mus musculus) brain. J Comp Neurol 2013; 521: 2321-2358.
49. Forbes-Lorman RM, Rautio JJ, Kurian JR, Auger AP, Auger CJ: Neonatal MeCP2 is important for the organization of sex differences in vasopressin expression. Epigenetics 2012; 7: 230-238.
50. Marshall JF, Belcher AM, Feinstein EM, O'Dell SJ: Methamphetamine-induced neural and cognitive changes in rodents. Addiction 2007; 102(suppl 1):61-69. (Pubitemid 46328218)
51. Yu J, Cadet JL, Angulo JA: Neurokinin-1 (NK-1) receptor antagonists abrogate methamphetamine-induced striatal dopaminergic neurotoxicity in the murine brain. J Neurochem 2002; 83: 613-622. (Pubitemid 35231815)